Is AMICUS THERAPEUTICS, INC. (FOLD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 9.8% / 30% | 6.5% / 30% | 2.6% / 30% | 0.52% / 5% | ✓ HALAL |
| DJIM | 9.8% / 33% | 6.5% / 33% | 2.6% / 33% | 0.52% / 5% | ✓ HALAL |
| MSCI | 46.6% / 33% | 30.9% / 33% | 12.1% / 33% | 0.52% / 5% | ✗ NOT HALAL |
| S&P | 9.8% / 33% | 6.5% / 33% | 2.6% / 33% | 0.52% / 5% | ✓ HALAL |
| FTSE | 46.6% / 33% | 30.9% / 33% | 12.1% / 50% | 0.52% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 88.5% | |
| Operating Margin | 8.6% | |
| Net Margin | -4.3% | |
| Return on Equity (ROE) | -11.6% | |
| Return on Assets (ROA) | 2.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $33M |
| Free Cash Flow | $30M |
| Total Debt | $442M |
| Debt-to-Equity | 161.3 |
| Current Ratio | 2.8 |
| Total Assets | $950M |
Price & Trading
| Last Close | $14.43 |
| 50-Day MA | $14.34 |
| 200-Day MA | $10.03 |
| Avg Volume | 7.0M |
| Beta | 0.5 |
|
52-Week Range
$5.51
| |
About AMICUS THERAPEUTICS, INC. (FOLD)
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Purification Calculator
As a halal stock with 0.52% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AMICUS THERAPEUTICS, INC. (FOLD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AMICUS THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AMICUS THERAPEUTICS, INC.'s debt ratio?
AMICUS THERAPEUTICS, INC.'s debt ratio is 9.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 46.6%.
Does AMICUS THERAPEUTICS, INC. require dividend purification?
Yes, AMICUS THERAPEUTICS, INC. has an impermissible income ratio of 0.52%, which means 0.52% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are AMICUS THERAPEUTICS, INC.'s key financial metrics?
AMICUS THERAPEUTICS, INC. has a market capitalization of $4.5B, and revenue of $634M. The company maintains a gross margin of 88.5% and a net margin of -4.3%. Return on equity stands at -11.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.